Showing posts with label heart. Show all posts
Showing posts with label heart. Show all posts
Tuesday, April 11, 2017
NEW class grateful heart journal GIVEAWAY!
NEW class grateful heart journal GIVEAWAY!
The Grateful HeART Journal
I believe that gratitude can completely transform your perspective and make your life better! In my darkest moments, it has been the practice of giving thanks that has truly saved me. There is something even more profound about writing or creating about gratitude. In this class I will be sharing 30 creative and simple art journal prompts, techniques and exercises that will inspire you to pay attention to the all the good things in your life!
Details and registration HERE
ENTER TO WIN-
Leave me a comment
Tell me something you are grateful for
I will announce the winners later this week!
WINNERS!
email me at alisaburke@gmail.com for access to class
Available link for download
Friday, April 7, 2017
NEW TYPE OF CHOLESTEROL LOWERING DRUG HALVES THE RISK OF HEART ATTACK OR STROKE STUDY REVEALS
NEW TYPE OF CHOLESTEROL LOWERING DRUG HALVES THE RISK OF HEART ATTACK OR STROKE STUDY REVEALS
People taking an experimental drug called Repatha (evolocumab) for high cholesterol were half as likely to die or suffer a heart attack or stroke as those taking conventional statins
New type of cholesterol-lowering drug halves the risk of a heart attack or stroke, study reveals
A new type of cholesterol-lowering drug may halve the risk of a heart attack or stroke, new research suggests.People taking the experimental drug for high cholesterol were half as likely to die or suffer a heart attack or stroke as those taking conventional statins.
- New class of drug could help those unable to tolerate regular statins
- Drug used in the trial, evolocumab, works differently to the type currently prescribed, such as Lipitor
- It blocks a harmful protein in the liver, freeing the organ up to remove bad LDL cholesterol from the blood
- US Government to decide in summer whether to approve this type of drug
A new type of cholesterol-lowering drug may halve the risk of a heart attack or stroke, new research suggests.People taking the experimental drug for high cholesterol were half as likely to die or suffer a heart attack or stroke as those taking conventional statins.
The results could offer an alternative to the estimated one in three Westerners with high cholesterol who have been unable to manage their condition with diet, exercise and statin drugs currently on the market.
The results are really impressive and very encouraging for the new drugs, said one independent expert, Dr Judith Hochman of NYU Langone Medical Center.The U.S. government will decide this summer whether to allow two of these drugs on the market.
The drugs are evolocumab, which Amgen wants to call Repatha, and alirocumab, which Regeneron Pharmaceuticals and Sanofi have named Praluent.
They lower LDL or bad cholesterol more powerfully and in a different way than existing drugs, by blocking PCSK9, a substance that interferes with the livers ability to remove cholesterol from the blood.Side effects remain a question, though, especially on thinking, confusion and memory - problems the FDA has already voiced concern about and asked the companies to track.
The results are really impressive and very encouraging for the new drugs, said one independent expert, Dr Judith Hochman of NYU Langone Medical Center.The U.S. government will decide this summer whether to allow two of these drugs on the market.
The drugs are evolocumab, which Amgen wants to call Repatha, and alirocumab, which Regeneron Pharmaceuticals and Sanofi have named Praluent.
They lower LDL or bad cholesterol more powerfully and in a different way than existing drugs, by blocking PCSK9, a substance that interferes with the livers ability to remove cholesterol from the blood.Side effects remain a question, though, especially on thinking, confusion and memory - problems the FDA has already voiced concern about and asked the companies to track.
The problems affected only 1 or 2 percent of patients and may be temporary, but they were twice as common among people taking one of the new drugs and need to be closely monitored as studies continue, said Dr. Anthony DeMaria, a University of California at San Diego heart specialist and past president of the American College of Cardiology.
As a patient facing potential side effects, the last one I want is one that affects the brain, he said.
HOW DO THE DRUGS WORK?
Evolocumab works differently than traditional statins.
It is a human monoclonal antibody that blocks a harmful protein in the liver, freeing the organ up to remove bad LDL cholesterol from the blood.
This new class of drug is known as a PCSK9 inhibitor, and three different kinds, including evolocumab, are being studied in large clinical trials.
Previous research has shown evolocumab could lower LDL or bad cholesterol - the kind that contributes to plaque buildup in the arteries - by 61 percent.The findings were based on 4,465 patients who were studied for one year after completing an earlier phase of the drugs safety and efficacy testing.
Patients were selected at random to receive either receive evolocumab, made by the pharmaceutical company Amgen, injected under the skin in addition to standard care.
As a patient facing potential side effects, the last one I want is one that affects the brain, he said.
HOW DO THE DRUGS WORK?
Evolocumab works differently than traditional statins.
It is a human monoclonal antibody that blocks a harmful protein in the liver, freeing the organ up to remove bad LDL cholesterol from the blood.
This new class of drug is known as a PCSK9 inhibitor, and three different kinds, including evolocumab, are being studied in large clinical trials.
Previous research has shown evolocumab could lower LDL or bad cholesterol - the kind that contributes to plaque buildup in the arteries - by 61 percent.The findings were based on 4,465 patients who were studied for one year after completing an earlier phase of the drugs safety and efficacy testing.
Patients were selected at random to receive either receive evolocumab, made by the pharmaceutical company Amgen, injected under the skin in addition to standard care.
Or, they received standard care alone, which meant taking the cholesterol-lowering statin drug recommended by their physician.
The drug has yet to be approved by the US Food and Drug Administration, and more years of study are planned to test its longer term outcomes.
The drug has yet to be approved by the US Food and Drug Administration, and more years of study are planned to test its longer term outcomes.
But after one year, the analysis showed the rate of cardiovascular events - such as death, heart attack, stroke, hospitalisation or surgery to open blocked arteries - in the evolocumab group was 0.95 percent.
This was compared to 2.18 percent in the traditional statin group, most of whom were taking moderate or high intensity regimens of the cholesterol-lowering drugs.
+2High cholesterol is a major risk factor for heart disease, the leading killer worldwide. Yet one in three Westerners are unable to manage their condition with diet, exercise and statin drugs currently on the market
The reduction in LDL was profound and that may be why we saw a marked reduction in cardiovascular events so quickly, said lead author Marc Sabatine, senior physician in the Division of Cardiovascular Medicine at Brigham and Womens Hospital in Boston.
It suggests that if we can drive a patients LDL cholesterol down a large amount to a very low level, we may start to see a benefit sooner than would be expected with a more modest intervention.
High cholesterol is a major risk factor for heart disease, the leading killer worldwide.
This was compared to 2.18 percent in the traditional statin group, most of whom were taking moderate or high intensity regimens of the cholesterol-lowering drugs.
+2High cholesterol is a major risk factor for heart disease, the leading killer worldwide. Yet one in three Westerners are unable to manage their condition with diet, exercise and statin drugs currently on the market
The reduction in LDL was profound and that may be why we saw a marked reduction in cardiovascular events so quickly, said lead author Marc Sabatine, senior physician in the Division of Cardiovascular Medicine at Brigham and Womens Hospital in Boston.
It suggests that if we can drive a patients LDL cholesterol down a large amount to a very low level, we may start to see a benefit sooner than would be expected with a more modest intervention.
High cholesterol is a major risk factor for heart disease, the leading killer worldwide.
The study, which was funded by the drugmaker, Amgen, showed few cardiovascular events among both groups - just 60 in total, so more data from a long-term study of 27,000 people expected in 2017 should shed more light on the drugs effectiveness.
The FDA may decide to make the treatment available after an expected review of the data later this year.
We wont have any definitive answers until this larger trial we are doing is complete, but these data now give us a sense for the potential clinical benefit of these drugs, Sabatine said.
The results were presented at the American College of Cardiology annual conference in San Diego, California, and published simultaneously in the New England Journal of Medicine.source.www.dailymail.co.uk
We wont have any definitive answers until this larger trial we are doing is complete, but these data now give us a sense for the potential clinical benefit of these drugs, Sabatine said.
The results were presented at the American College of Cardiology annual conference in San Diego, California, and published simultaneously in the New England Journal of Medicine.source.www.dailymail.co.uk
Available link for download
Wednesday, March 15, 2017
New Heart touching Nepali lok song 2073 2016 Timile Diyako Chino Sagar Birahi Video HD
New Heart touching Nepali lok song 2073 2016 Timile Diyako Chino Sagar Birahi Video HD
Sangam Digital Pvt Ltd Presnets
In Lyrics and Music of Seru Nigam Pariyar and T.B. Santosh Pariyar
Mobile Ringback Tone Code For this Song
PRBT : 60546907
New Nepali Lok Dohori Folk Song "Timile Diyeko Chino"
More Details About This Song
Sangam Digital Presents :- Heart touching Nepali lok song
song:- Timile Diyako Chino
Vocal:- Sagar Birahi
Lyrics/Music:- Seru Nigam Pariyar & T.B. Santosh Pariyar
Arrange:- Sagar Birahi
Audio/video:- Sangam Digital Pvt. Ltd. 9849113669, 9851194081
Director:- Kapil Lama
Cinematographer:- Rajesh Ghimere
Editor:-Sujan Shahi
Model:- Sagar Birahi / Dewaa Gharti Magar
Post Production:- Om Shiva Films
Available link for download
Tuesday, February 14, 2017
Nic November Wild at Heart and The Wicker Man
Nic November Wild at Heart and The Wicker Man
Well, here we are at the end of an interesting month of devouring a whole bunch of Nicolas Cage movies. I cant really say Im thinking that he is now a great actor, but this experience has definitely opened my eyes to his...wide array of talents. Especially this week, as I left Wild at Heart and The Wicker Man until last.
The Hairstyle: The Carefree 90s Punk-Rock/Boy Band Cross-Over
One of the main reasons why I added Wild at Heart to the list - and why I left it until last - was because it is a David Lynch film. And I thought that Lynch + Nicolas = more craziness than you could imagine. And I was right. Wild at Heart is one of the strangest movies Ive ever seen, even though I suppose it is more sane and easy to follow than some of Lynchs other stuff. To be honest, theres just a whole lot of sex. Like...a lot. Honestly, it was just the basis for the entire film. There was a story of Sailor (Cage) and his 20 year old girlfriend Lula (Laura Dern) getting chased down by a gang that Lulas mother (Diane Ladd) assembled because she doesnt approve of Sailor. The gang itself is pretty crazy, mainly because it involves Willem Dafoe being crazy. But at any rate, this is just an interesting take on a road trip movie melded with a love story.
In fact, the love story was probably the best thing this movie had going for it. It was like, a partially insane coming-of-age story intertwined with tones of The Wizard of Oz. And it has Nicolas Cage singing Love Me Tender at the end, which was interesting. Nicolas himself was actually very good, but that comes with the insanity of the material - Ive found that the more insane the material is, the more tolerable he is. Sailor is just a cool dude in a snakeskin jacket, and the role isnt all that demanding to be honest. If Nicolas had taken Willem Dafoes role, then things would have gone absolutely crazy. However, Dafoe did a terrifying job all by himself (hes no Dennis Hopper in Blue Velvet but theres shades of that character in his character). I cant say I loved the film, but I definitely enjoyed it, I guess. An interesting entry to the David Lynch cannon, thats for sure.
Cage Rage:
The Hairstyle: IDGAF
So anyway, the one Ive eagerly been awaiting: The Wicker Man. Yes, it is as bad as I previously thought I was going to be. Seriously, I dont even know where it was going. It was just so poorly made and scripted, and definitely wasnt at all scary because it tried to hard. It really did try too hard to be everything that it couldnt be. And you know why?
Because it had Nicolas Cage in a bear suit.
I dont care if this was the best film ever made, Nicolas Cage in a bear suit brings down a whole movie. Luckily it occurred towards the end of the film, because I had trouble taking anything seriously at that point. Mind you, I couldnt take this film seriously because it took itself too seriously. It was kind of sad to watch.
One person that wasnt taking themselves terribly seriously, though, was good old Cage. He wasnt even trying. It is like how you feel when youre really tired so you just weakly beg and plead with people to listen to you. When he was saying "howd it get burned? Howd it get burned?", he really had the life sucked out of him. And then there was that bear suit, which is something Ill never forget, thats for sure.
It was just a really bad movie. Im not even sure it was "so bad its good". I do have to wonder why James Franco turned up at the end. That was strange...
Cage Rage:
The quality of the Nic November movies, ranked:
8. The Wicker Man (2006) Dir. Neil LaBute
7. Ghost Rider (2007) Dir. Mark Steven Johnson
6. Gone in 60 Seconds (2000) Dir. Dominic Sena
5. Bad Lieutenant: Port of Call New Orleans (2009) Dir. Werner Herzog
4. Wild at Heart (1990) Dir. David Lynch
3. Lord of War (2005) Dir. Andrew Niccol
2. Face/Off (1997) Dir. John Woo
1. Adaptation. (2002) Dir. Spike Jonze
What did I think of my experience as a whole?
To be honest, I dont know how it has gone so fast. I thought this would be a torturous month, but there were some real surprises in the mix here. Still, Nicolas Cage isnt a great actor to me. He is capable of greatness, though. In small doses.
And that is the end of me dipping my toes in anything for the year! Sometime during the weekend/after I do my Magic Mike review there will be a huge post up looking back at all four of the different realms Ive explored this year. For now, though: what do you think of these films? And how do you feel about Nicolas Cage?
Available link for download
Subscribe to:
Posts (Atom)